Clinical Trial Update: An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II [Phase 2, Phase 3]

View source ↗

Summary

An open prospective randomized trial evaluating intraperitoneal Prospidelong gel for gastric cancer with peritoneal dissemination; Phase 2/3, currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer with Peritoneal Metastasis

Drugs mentioned

• Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1

Snippet

Sponsor: Research Institute for Physical Chemical Problems of the Belarusian State University | Conditions: Gastric Cancer With Peritoneal Dissemination | Phase 2, Phase 3 | Status: RECRUITING